Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665255 | 1.00 | ALOX15 (0.39) | ALOX15CASP1GAACASP7ALK | |
| SCHEMBL16294313 | 0.85 | ALOX15 (0.39) | ALOX15CASP1ERN1BCL2MCL1 | |
| Hydrochloric Acid SCHEMBL29015486 | 0.83 | ALOX15 (0.38) | ALOX15CASP1ERN1BCL2MCL1 | |
| SCHEMBL12861090 | 0.77 | SRC (0.32) | — | |
| SCHEMBL4297621 | 0.77 | NT5E (0.49) | GAAALKPIM1CHEK1AKT1 | |
| SCHEMBL30950664 | 0.77 | NT5E (0.49) | GAAALKPIM1CHEK1AKT1 | |
| SCHEMBL29665280 | 0.77 | NT5E (0.49) | GAAALKPIM1CHEK1AKT1 | |
| SCHEMBL12034330 | 0.77 | TRPA1 (0.45) | ALOX15GAAIDO1LMNAMAPT | |
| SCHEMBL9998167 | 0.77 | ERN1 (0.37) | ERN1 | |
| SCHEMBL2719952 | 0.77 | KDM4E (0.44) | HTTIDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4493562-A1 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-118388416-A | Synthesis method of 4-chloro-6-bromocinnoline | 凯美克(上海)医药科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240207263-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4308569-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | Suzhou Zanrong Pharma Limited (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-117412972-A | Selective modulators of Ataxia Telangiectasia Mutated (ATM) kinase and uses thereof | 苏州赞荣医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023178235-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178235-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022193166-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022194138-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2022-09-22 | — | — | WO | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| EP-2616468-A1 | FUSED HETEROARYLS AND THEIR USES | Hutchison Medipharma Limited (CN) | 2013-07-24 | — | — | EP | disclosed |
| CN-103124731-A | Fused heteroaryl compounds and uses thereof | HUTCHISON MEDIPHARMA LTD | 2013-05-29 | — | — | CN | disclosed |
| CN-102399218-A | Triheterocyclic compounds and their use as PI3K inhibitors | HUTCHISON MEDIPHARMA LTD | 2012-04-04 | — | — | CN | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | ALOX15 1980/4885CASP1 1831/4885GAA 3318/4885 |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | ALOX15 2675/4885CASP1 2297/4885GAA 2258/4885 |
| US-20240207263-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | ATM, CHEK2, CHEK1 | ALOX15 4651/4885CASP1 2793/4885GAA 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.